Concepedia

Charles G. Cerveny

CG

Statistics

Publications

19

Citations

5.4K

H-Index

16

Active since

1996

Affiliations

Seagen (United States)(Current)

University of Washington

Molecular Oncology (United States)

Charles G. Cerveny is an author at Seagen (United States) specializing in oncology, antibody-drug conjugates, and antibody conjugates.

Publications per year

1996–2006

19

Publications

19

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett, Peter D. Senter, Dana F. Chace et al. · Clinical Cancer Research · 2004 · 1.2K citations

, , +17

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

Svetlana O. Doronina, Brian E. Toki, Michael Torgov et al. · Nature Biotechnology · 2003 · 1.2K citations

, , +14

cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity

Joseph A. Francisco, Charles G. Cerveny, Damon L. Meyer et al. · Blood · 2003 · 921 citations

, , +11

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina, Brian A. Mendelsohn, Tim D. Bovee et al. · Bioconjugate Chemistry · 2005 · 512 citations

, , +17

Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides

Michael Sun, Kevin S. Beam, Charles G. Cerveny et al. · Bioconjugate Chemistry · 2005 · 365 citations · Full text

, , +17

1–5 of 19